Apical membrane antigen 1 protein (AMA1)

Apical membrane antigen 1 protein (AMA1) is an integral membrane protein expressed in the apical complex of invasive forms (merozoites and sporozoites) of Plasmodium species, including Plasmodium falciparum and Plasmodium vivax[2][3][4][6]. It is synthesized as an ~83 kDa precursor and processed to a lower-molecular-weight form during parasite maturation[4][5]. Structurally, AMA1 features a signal sequence, a cysteine-rich ectodomain subdivided into three domains (I–III), a transmembrane region, and a conserved cytoplasmic tail[2][4][6]. Its ectodomain mediates critical interactions with the parasite protein RON2 to form a complex essential for host cell invasion[1][6][8]. AMA1 is a highly immunogenic antigen, and the immune responses (notably antibodies) it elicits can inhibit erythrocyte invasion; for this reason, it is a major vaccine candidate for blood-stage malaria[2][5][7]. However, extensive polymorphism—particularly in domain I—limits the ability of antibodies or vaccines based on AMA1 to provide broad, strain-transcending immunity, making antigenic diversity a central challenge for its clinical exploitation[2][6][7]. No therapeutics directly targeting AMA1 are currently approved, but ongoing vaccine development and small molecule inhibitor research continue[2][5][8].

Other names

AMA-1Apical membrane antigen-1PK66 (in Plasmodium knowlesi)PfAMA1 (Plasmodium falciparum AMA1)PvAMA1 (Plasmodium vivax AMA1)

Blockade of AMA1-RON2 interaction interrupts merozoite invasion of host cells[1][8]. Induction of antibodies that inhibit parasite entry into red blood cells[2][5][7].